Daiichi Sankyo Company, Limited and Gustave Roussy announced a multi-year, multi-study research collaboration to enrich and further enable the development of DS-1062 and patritumab deruxtecan, two of Daiichi Sankyo’s lead DXd antibody drug conjugates, in lung and breast cancer.
Scientists investigated tumor-associated macrophage (TAM) subtype density and distribution between tumor center and invasive margin in human lung cancer and TAM associations with overall survival.
1254621 PGW6HIVH items 1 apa default asc 1
The authors provide an overview of current advancements in understanding the role of cell–cell interaction in the development of acute lung injury (ALI) and depict molecular mechanisms by which cell–cell interactions regulate lung inflammation, focusing on inter-cellular activities and signaling pathways that point to possible therapeutic opportunities for ALI/acute respiratory distress syndrome.
1254621 BRSZTP7T items 1 apa default asc 1
Lantern Pharma announced entering into agreements with leading contract manufacturing companies for process development and manufacturing for two of Lantern’s oncology drug candidates, LP-300 and LP-184.
[Lantern Pharma Inc.]
Continue reading “Lantern Pharma Establishes Manufacturing Network in Preparation for Its Phase II Clinical Trial for the Treatment of Non-Small Cell Lung Cancer and a Phase I Clinical Trial for Solid Tumors and Glioblastoma”
The authors profile single-cell transcriptomes of genetically engineered mouse lung tumors at seven stages, from pre-neoplastic hyperplasia to adenocarcinoma.
1254621 ICFFXRMS items 1 apa default asc 1
Scientists used single-cell epigenomics to profile chromatin state transitions in a mouse model of lung adenocarcinoma. They identified an epigenomic continuum representing loss of cellular identity and progression toward a metastatic state.
1254621 I3RVA22D items 1 apa default asc 1
The authors investigated the role of NRF2 in resistance to epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs). They showed that NRF2 protein levels were markedly increased in a panel of EGFR-TKI-resistant non-small cell lung cancer cell lines due to slow degradation of NRF2 protein.
[Acta Pharmacologica Sinica]
1254621 NBEGL9TG items 1 apa default asc 1
For the hundreds of thousands of people enrolling in clinical trials every year—and for whom experimental therapies can offer a last hope—a new report provides some welcome news: Enrollment in clinical studies in the United States is on the rebound after disruptions caused by the COVID-19 pandemic.
A historic €1.8-trillion (US$2.1-trillion) budget deal reached by European Union (EU) leaders to fund its next seven years — and its recovery from the coronavirus pandemic — has left scientists and research advocates disappointed.
Researchers used reconstituted human airway epithelia to isolate and then characterized the viral infection kinetics, tissue-level remodeling of the cellular ultrastructure, and transcriptional early immune signatures induced by SARS-CoV-2 in a physiologically relevant model.
[Cell Reports Medicine]
1254621 DW49WPCP items 1 apa default asc 1
Investigators develop a method for 8-oxo-7,8-dihydroguanine profiling using immunocapturing and RNA sequencing. They found 42 oxidized transcripts in bronchial epithelial BEAS-2B cells exposed to two air pollution mixtures that recreate urban atmospheres.
1254621 U9489CLC items 1 apa default asc 1
Gonzalez-Rivera, J. C., Baldridge, K. C., Wang, D. S., Patel, K., Chuvalo-Abraham, J. C. L., Hildebrandt Ruiz, L., & Contreras, L. M. (2020). Post-transcriptional air pollution oxidation to the cholesterol biosynthesis pathway promotes pulmonary stress phenotypes. Communications Biology, 3(1), 1–16. https://doi.org/10.1038/s42003-020-01118-6 Cite
Sanford Burnham Prebys Medical Discovery Institute has received an award from the California Institute for Regenerative Medicine to advance promising drug candidates for COVID-19.
[Sanford Burnham Prebys Medical Discovery Institute]